Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Common Equity (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Common Equity for 6 consecutive years, with $874714.0 as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 86.71% to $874714.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $874714.0, a 86.71% decrease, with the full-year FY2024 number at $3.4 million, up 618.98% from a year prior.
  • Common Equity was $874714.0 for Q3 2025 at Ensysce Biosciences, down from $3.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $6.6 million in Q3 2024 to a low of -$8.2 million in Q4 2021.
  • A 5-year average of $254986.1 and a median of $1.1 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: plummeted 1566.79% in 2022, then soared 2344.15% in 2024.
  • Ensysce Biosciences' Common Equity stood at -$8.2 million in 2021, then surged by 50.61% to -$4.0 million in 2022, then skyrocketed by 83.84% to -$651267.0 in 2023, then skyrocketed by 618.98% to $3.4 million in 2024, then tumbled by 74.12% to $874714.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Common Equity are $874714.0 (Q3 2025), $3.1 million (Q2 2025), and $2.7 million (Q1 2025).